Chelsea Therapeutics names Joseph Oliveto as president and CEO
US biotech firm Chelsea Therapeutics’ (Nasdaq: CHTP) has named Joseph Oliveto as president and chief executive officer and a member of the company's board of directors, effective January 22.
Mr Oliveto (pictured) had served as the company's interim president and chief executive officer since July 2012. Mr Oliveto joined Chelsea following a two-year assignment as Executive in Residence at Pappas Ventures, a life sciences venture capital firm.
Michael Weiser, chairman of the board, said: “Joe has demonstrated thoughtful and steadfast leadership through a demanding period for Chelsea, resulting in important progress for the company and its lead drug candidate, Northera. The Board of Directors looks forward to his continued contributions as we work toward delivering a new treatment option to patients with neurogenic orthostatic hypotension.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze